Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 1;18(5):273-279.
doi: 10.1097/COH.0000000000000814. Epub 2023 Jul 18.

The changing use and program costs of HIV-related laboratory testing over 20 years in an HIV cohort

Jessica Dalere  1   2 , Raynell Lang  1   2   3 , Hartmut B Krentz  1   2 , Brenda Beckthold  1   2 , M John Gill  1   2   4
Affiliations
Review

The changing use and program costs of HIV-related laboratory testing over 20 years in an HIV cohort

Jessica Dalere et al. Curr Opin HIV AIDS. .

Abstract

Purpose of review: The improved health of persons with HIV (PWH) resulting from antiretroviral therapy (ART) has led to recommendations for reduced laboratory monitoring. We studied, for all PWH in care over 20 years at the Southern Alberta Clinic (SAC), Canada, the changing use and results of HIV-specific laboratory testing [i.e., CD4+ testing, plasma HIV viral load (PVL), and genotypic antiretroviral resistance testing (GART)].In this descriptive retrospective longitudinal cohort observational study, we examined HIV-specific laboratory testing for all PWH from 2000 to 2020 within the context of HIV-related health outcomes, program costs, and mortality.

Recent findings: The number of PWH in care increased from 755 in 2000 to 2050 in 2020. Annual CD4+ testing per PWH increased from 2.7 per person in 2000 peaking to 3.5 in 2005 but decreasing to 1.4 by 2020. Annual PVL tests per PWH gradually decreased from 3.2 in 2000 to 2.0 in 2020. GART increased from 93 tests in 2000 to 315 in 2008 decreasing to 127 in 2020. Patients received GART at baseline, and after a viral breakthrough when indicated. Viral suppression rates for the population increased from 66 to 96%; median CD4+ cell count increased from 443 to 470 cells/μl, and overall morbidity decreased from 9.2 to 2.0% by 2020, respectively. Annual per patient laboratory costs decreased from a high of $302 in 2008 to $161 by 2020.

Summary: The reduced annual laboratory surveillance per PWH associated with modern ART resulted in modest cost savings and no apparent loss in quality of HIV care.

PubMed Disclaimer

References

    1. Farel CE, Dennis AM. Why everyone (almost) with human immunodeficiency virus needs to be on treatment: a review of the critical data. Infect Dis Clin North Am 2019; 33:663–679.
    1. The Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372:293–299.
    1. Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One 2013; 8:e81355.
    1. Krentz HB, Vu Q, Gill MJ. Updated direct costs of medical care for HIV-infected patients within a regional population from 2006 to 2017. HIV Med 2019; 21:289–298.
    1. Clutter DS, Jordan MR, Bertagnolio S, et al. HIV-1 drug resistance and resistance testing. Infect Genet Evol 2017; 46:292–307.

LinkOut - more resources